Oscar Health (OSCR) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oscar Health (OSCR) has outperformed Progyny (PGNY) over the past year, gaining 51.8% versus a gain of 35.2%. Over five years, OSCR leads with a +108.8% price change compared with -50.3% for PGNY. Oscar Health is the larger company by market cap ($10.30 billion vs $2.15 billion), about 4.8 times the size.
On valuation, Progyny trades at a lower forward P/E (12.1x vs 15.4x for Oscar Health). Progyny converts more of its revenue into profit, with a net margin of 4.5% versus -3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSCR | PGNY |
|---|---|---|
| Share price | $33.37 | $28.00 |
| Market cap | $10.30B | $2.15B |
| 1-day change | +0.80% | +0.61% |
| YTD return | +130.34% | +8.37% |
| 1-year return | +51.83% | +35.23% |
| 5-year return | +108.83% | -50.29% |
| P/E ratio (TTM) | 25.86 | 30.43 |
| Forward P/E | 15.41 | 12.07 |
| EPS (TTM) | $1.29 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $11.70B | $1.29B |
| Revenue growth (YoY) | +27.50% | +10.40% |
| Net income (latest FY) | $-443.15M | $58.52M |
| Gross margin | — | 23.63% |
| Operating margin | -3.39% | 6.62% |
| Net margin | -3.79% | 4.54% |
| 52-week high | $34.48 | $33.07 |
| 52-week low | $10.69 | $16.10 |
| Distance from 52-week high | -3.23% | -15.32% |
| Analyst consensus | hold | none |
| Avg. price target upside | +6.10% | +22.93% |
| Average volume | 5.20M | 1.15M |
| Shares outstanding | 273.47M | 76.73M |
| Employees | 2,305 | 835 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oscar Health is about 4.8 times larger than Progyny by market value ($10.30B vs $2.15B).
- OSCR has outperformed PGNY by 16.6 percentage points over the past year.
- Progyny is more profitable, keeping 4.5 cents of every revenue dollar as net income versus -3.8 cents for Oscar Health.
- Oscar Health grew revenue faster in its latest fiscal year (+27.50% vs +10.40%).
About Oscar Health
OSCR stock →Oscar Health, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 2,305 employees
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
OSCR vs PGNY FAQ
Which is bigger, Oscar Health or Progyny?
Oscar Health (OSCR) is larger, with a market capitalization of $10.30B compared with $2.15B for Progyny (PGNY).
Which stock has performed better over the past year, OSCR or PGNY?
OSCR returned +51.83% over the past 12 months, compared with +35.23% for PGNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, OSCR or PGNY?
OSCR has the lower trailing P/E at 25.9, versus 30.4 for PGNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Oscar Health and Progyny in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Oscar Health and Misc Health and Biotechnology Services for Progyny.